IRDiRC: International Rare Diseases Research Consortium

Similar documents
Aims of the International Workshop

Information Day Leeds, UK 27 October 2015 Treating and managing disease

Science, Demographic Change and Wellbeing in Horizon 2020

International networks and DMD registries. Hanns Lochmüller, Newcastle University

IRDiRC: Stepping stones towards success Ruxandra Draghia-Akli, MD, PhD, Deputy Director-General

TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University

The International Consortium for Personalised Medicine

Rare Diseases: Challenges and Opportunities NIH Perspective

TREAT-NMD Curators Meeting, Istanbul, 29 th September TREAT-NMD Alliance Update new governance structure and

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Reti europee ed internazionali per la ricerca scientifica per le malattie rare

- OMICS IN PERSONALISED MEDICINE

6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels

The Curative and Transformative Potential of Novel Therapies for Rare Diseases in the Age of Precision Medicine

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

Nordic Common Strengths and Future Potential in the Field of Personalised Medicine

Meeting report series. Report of the 4th Therapies Scientific Committee Meeting

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y

ERNs and Research - State of play from the European Commission perspective

Topic: Genome-Environment Interactions in Inflammatory Skin Disease

PROJECT FINAL REPORT. Project website Erreur! Signet non défini. address:

Global registries for rare diseases: challenges and solutions

The Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain

EUROPLAN NATIONAL CONFERENCES CONTENT GUIDELINES FOR WORKSHOP 3 / THEME 3 RESEARCH FOR RARE DISEASES

Comments about Rare diseases: Europe s challenge from the Public and Professional Policy Committee of the European Society for Human Genetics.

KPI Definition Comment Relates to Baseline Target

Personalised Medicine Conference 2016

Innovative Medicines Initiative - the story so far

Challenges of Personalized Health for Clinical Medicine. Peter J Meier-Abt Swiss Academy of Medical Sciences (SAMS) Berne, Switzerland

Personalised Medicine Regulatory Issues

Personalized. Health in Canada

Molecular Diagnostics

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

Novartis Response to the Commission Consultation. Rare Diseases: Europe s Challenge

1.0 Background to the organisation

Exemplary Project. COILED THE NETHERLANDS April 2018

Why Culture Matters in Cancer Research

Towards an EU Platform on Rare Diseases Registration

Orphan designation in the EU

The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels

Precision Medicine Catapult

Understanding the impact of publications in specialist areas: focus on orphan drugs

Translational Research

The importance of international collaboration for rare diseases research: a European perspective

Nanotechnology and Advanced Materials for more effective Healthcare

EU support for Health Research from FP6 to FP7

Innovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium

Innovative Medicines Initiative

The experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018

Strategic Research Agenda of E-Rare in relation to other initiatives on rare diseases

Data Warehouse Systems at the German Centers for Health Research (DZG)

Use of Big Data to Support Regulatory Decision Making

Progress in Rare Diseases Research : An IRDiRC Perspective

A whole-system approach to delivering personalised medicine and health in Leeds. Mike Messenger

Centre for NanoHealth

ABPI response to European Commission consultation on advanced therapy medicinal products

Per Morten Sandset Japan-UiO cooperation within health and care research status and opportunities

Interpreting Genome Data for Personalised Medicine. Professor Dame Janet Thornton EMBL-EBI

Genomics and personalised medicine

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England

From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014

RARE DISEASE DAY CONFERENCE 2018: Building on Research Excellence to Improve Patient Care Two-Day Interactive Conference

E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager

Neurodegeneration and other neuroscience priorities

Biotechnology Activities at the National Institutes of Health: Priorities and Trends. US-EU Task Force on Biotechnology Brussels, July, 2006

Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients

Biomarkers as an emerging growth area in Denmark

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.

Meeting report series. Report of the 12th Diagnostics Scientific Committee Meeting

Supplementary Materials for

Roche in Australia Innovation Leader

Patient-Led Initiative to Identify the Molecular Cause of Rare Inherited Retinopathies

SPECTArare as an innovative model of combining clinical research and care in an ERN. Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium

NATIONAL INSTITUTES OF HEALTH

ENVIRONMENT, PUBLIC HEALTH AND FOOD SAFETY (ENVI) Personalised Medicine - Current Status KEY FINDINGS

Using local RWD to drive global therapeutic advancements.

Christoph Bock ICPerMed First Research Workshop Milano, 26 June 2017

US Food and Drug Administration. Sandra L. Kweder, MD Deputy Director, Europe Office

Open Innovation March 2014

EU Big Data Initiatives

NHS ENGLAND BOARD PAPER

PERSONALISED MEDICINE FOR THE BENEFIT OF PATIENTS

The Seventh Framework Programme ( )

The contribution of the Central & Eastern European Genetic Network (CEEGN) towards prevention and treatment of genetic diseases

While individually rare, orphan diseases are actually collectively common, with an OF ORPHAN DRUG DEVELOPMENT MEETING THE UNIQUE CHALLENGES

All research lines at the LMU have a strong methodological focus

EUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008

Innovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research. Krakow Biotechnology congress - 13 October 2011

MRC Stratified Medicine Initiative

Workshop 2 Getting involved in Research How can patient organizations trigger an EUfunded rare disease project?

8 th STAMP expert group meeting

Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013

EBE White Paper on Personalised Medicine

Question 1: Better codification and classification of RD Yes, we agree. Question 2: Establishment of an inventory of RD Yes I agree.

Orphan designation in the EU

This video gives an overview of the centralised procedure at the European Medicines Agency

Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017

Transcription:

IRDiRC: International Rare Diseases Research Consortium EuRenomics, NEUROMICS and RD-Connect Joint Kick-off Meeting Sitges, Spain, 25 January 2013 Dr. Iiro Eerola Scientific Project Officer Unit for Personalised Medicine Directorate for Health Directorate-General for European Commission

The EU: A major player in funding health research in rare diseases Over two decades of investment in the area Over 430 million invested in current programme More than 80 collaborative research projects launched in FP7 Continued strong investment through the next funding programme foreseen Gino Santa Maria/Fotolia.com

Research challenges related to rare diseases are too big to master alone Huge unmet medical needs for patients across the globe Scarce research resources Small patient populations Scattered knowledge Limited harmonisation of information and data yurii bezrukov /Fotolia.com

Co-operation at international level to stimulate, better coordinate & maximise output of rare disease research efforts around the world

nyul/fotolia.com Yuri Arcurs/Fotolia.com IRDiRC vision and 2020 goals in rare diseases research 200 New Therapies Means to Diagnose Most Rare Diseases

IRDiRC basic principles Teams up public and private organisations investing in rare diseases research Research funders with relevant programmes >$10 million US over a 5-year period can join Small funders may form a group of funders Each organisation funds research its own way Funded projects adhere to a common framework

rtguest/fotolia.com 29 committed members Europe E-RARE Consortium (EU) European Commission (EU) EURORDIS (EU) French Association against Myopathies (FR) French National Research Agency (FR) German Federal Ministry of Education and research (DE) Italian Higher Institute of Health Research (IT) Italian Telethon Foundation (IT) Lysogene (FR) Netherlands Organisation for Health Development Prosensa (NL) Shire (IE) Spanish Carlos III Health Institute (ES) UK National Institute for Health Research (UK) Australia Western Australian Department of Health North America Canadian Institutes for Health Research (CA) FDA Orphan Products Grants Program (US) Genome Canada (CA) Genetic Alliance (US) Mendelian Disorders Genome Centres (US) National Centre for Translational Therapeutics (US) National Cancer Institute (US) National Institute of Neurological Disorders and Stroke (US) National Institute of Arthritis and Musculoskeletal and Skin Diseases (US) National Institute of Child Health and Human Development (US) National Eye Institute (US) NORD (US) Office of Rare Diseases (US) Sanford Research (US)

Executive Committee Chair Ruxandra Draghia-Akli IRDiRC Governance Structure Diagnostics Chair Kym Boycott Scientific Committees Interdisciplinary Chair Hanns Lochmueller Therapies Chair Josep Torrent-Farnell Working Groups Names and biographies of appointed members on IRDiRC website: http://ec.europa.eu/research/health/»» click on to rare diseases research

Working Groups IRDiRC Working Groups Ontologies, disease prioritisation Sequencing Ethics and governance Registries and natural history Biomarkers Repurposing, small molecules Model systems Genome / Phenome Biobanks Bioinformatics, data sharing Advanced therapies Regulatory aspects / Bottlenecks FP7-funded SUPPORT-IRDiRC provides organisational support for Scientific Committees and Working Groups Coordinator: Prof. Ségolène Aymé, INSERM

EURenOmics: Rare kidney disorders New EU-funded IRDiRC projects NEUROMICS: Rare neuromuscular and neurodegenerative disorders Molecular characterisation of a large group of rare diseases using omics technologies Ontologies, reference omics profiles, diseases models, development of technologies Will lead to new means to diagnose and allow development of new treatments for these diseases

RD-Connect Platform for integrating omics data with clinical data Connecting registries, biobanks and clinical bioinformatics Supporting collection and storage of data and samples in EURenOmics and NEUROMICS Provides access to omics profiles and samples Will collaborate with other IRDiRC projects New EU-funded IRDiRC projects

Organisational support for IRDiRC SUPPORT-IRDiRC -Omics for better understanding of diseases in view of development of new diagnostics and treatments EURenOmics and NEUROMICS Databases, biobanks and clinical bio-informatics hub RD-Connect Preclinical and clinical development of orphan drugs DevelopAKure, DSD-Life, EUROFANCOLEN, MeuSIX, Net4CGD, ODAK, PROFNAIT, PREVENTROP, STRONG, Traumakine, Observational trials in rare diseases BESTCILIA, child-eu, DeSScipher, FIGHT-HLH, OPTIMISTIC Best practice and knowledge sharing in clinical management RARE-Bestpractices 20 projects on rare diseases launched in 2012

Topics related to rare diseases in the last FP7 Health Call (2013) HEALTH.2013.1.2-1: Development of imaging technologies for therapeutic interventions in rare diseases Min. 30 % EU Contribution to SME(s) HEALTH.2013.4.2-3: New methodologies for clinical trials for small population groups statistical design methodologies for clinical trials in particular for rare diseases or personalised medicine

Conference of the International Rare Diseases Research Consortium 2013 Dublin, 16-17 April 2013 http://ec.europa.eu/research/health/medicalresearch/rare-diseases/irdirc_en.html

Further information Information on research programmes and projects http://cordis.europa.eu/ EU research http://ec.europa.eu/research EU Health Research http://ec.europa.eu/research/health/index_en.h tml Seventh Framework Programme http://ec.europa.eu/research/fp7 FP7 Rare diseases http://ec.europa.eu/research/health/medicalresearch/rare-diseases/index_en.html Information requests http://ec.europa.eu/research/enquiries/